Optum guides providers through important upcoming formulary updates
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
July 1, 2024 - Formycon announced the FDA approval of Ahzantive (aflibercept-mrbb), biosimilar to Regeneron’s Eylea (aflibercept).
Download PDF
Return to publications
